Evidence map›Paper›PMID 30785348›Full record

ReviewAmerican journal of physiology. Renal physiology2019

Arteriovenous conduits for hemodialysis: how to better modulate the pathophysiological vascular response to optimize vascular access durability.

Yan-Ting Shiu, Joris I Rotmans, Wouter Jan Geelhoed, Daniel B Pike, Timmy Lee

Abstract readReview
In one paragraph

Review in American journal of physiology. Renal physiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Distal revascularization and interval ligation for femoral arteriovenous graft steal syndrome.Journal of vascular surgery cases and innovative techniques · 2026
    Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. The rodent models of arteriovenous fistula.Frontiers in cardiovascular medicine · 2024
    Review
  15. Article
  16. Article
  17. Article
  18. Vascular Cast to Program Antistenotic Hemodynamics and Remodeling of Vein Graft.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yan-Ting ShiuDivision of Nephrology, University of Utah , Salt Lake City, Utah.
Joris I RotmansDepartment of Internal Medicine, Leiden University Medical Center , Leiden , The Netherlands.
Wouter Jan GeelhoedDepartment of Internal Medicine, Leiden University Medical Center , Leiden , The Netherlands.
Daniel B PikeDivision of Nephrology, University of Utah , Salt Lake City, Utah.
Timmy LeeDepartment of Medicine and Division of Nephrology, University of Alabama at Birmingham , Birmingham, Alabama.

Funding

Nitric oxide releasing nanomatrix to enhance dialysis fistula maturationR44DK109789 · NIDDK · ENDOMIMETICS, LLC · PI CHEN, JUN · 2017 to 2022
$3.8M
Hemodynamic Adaptation and Vascular Remodeling in Fistula DevelopmentR01HL139692 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LEE, TIMMY C · 2018 to 2022
$2.1M
Mechanotransduction in Neointimal Hyperplasia Formation in Arteriovenous GraftsR01DK100505 · NIDDK · UNIVERSITY OF UTAH · PI SHIU, YAN-TING E. · 2014 to 2017
$1.3M
The Role of Endothelial Dysfunction in Arteriovenous Fistula MaturationI01BX003387 · VA · BIRMINGHAM VA MEDICAL CENTER · PI LEE, TIMMY C · 2017 to 2020
–
BLRD VA I01 BX003387BLRD VA I01 BX004133NHLBI NIH HHS R01 HL139692NIDDK NIH HHS R01 DK100505NIDDK NIH HHS R44 DK109789
6 · The paper itself

Abstract

Vascular access is the lifeline for patients on hemodialysis. Arteriovenous fistulas (AVFs) are the preferred vascular access, but AVF maturation failure remains a significant clinical problem. Currently, there are no effective therapies available to prevent or treat AVF maturation failure. AVF maturation failure frequently results from venous stenosis at the AVF anastomosis, which is secondary to poor outward vascular remodeling and excessive venous intimal hyperplasia that narrows the AVF lumen. Arteriovenous grafts (AVGs) are the next preferred vascular access when an AVF creation is not possible. AVG failure is primarily the result of venous stenosis at the vein-graft anastomosis, which originates from intimal hyperplasia development. Although there has been advancement in our knowledge of the pathophysiology of AVF maturation and AVG failure, this has not translated into effective therapies for these two important clinical problems. Further work will be required to dissect out the mechanisms of AVF maturation failure and AVG failure to develop more specific therapies. This review highlights the major recent advancements in AVF and AVG biology, reviews major clinical trials, and discusses new areas for future research.

Indexed as

Blood Vessel ProsthesisProsthesis FailureRenal DialysisAnimalsArteriovenous Shunt, SurgicalBlood Vessel Prosthesis ImplantationGraft Occlusion, VascularHumansProsthesis DesignRisk FactorsStress, MechanicalTreatment FailureVascular PatencyVascular Remodelingarteriovenous fistulaarteriovenous graftinflammationintimal hyperplasiaoutward remodeling

Identifiers

PMID30785348
PMCPMC6580244

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.